Dogness (International) Corp

Dogness (International) Corp Annual Report - Plain English Investor Review
Let’s break down what happened this year like we’re chatting over coffee…

---

Financial Health Check

China’s new money rules are squeezing flexibility:

• Dogness can’t use Renminbi (from foreign investments) for anything outside their core dog product business
• They’re banned from lending this money to unrelated companies
• Even simple operational changes (like factory upgrades) now require a 4-week foreign exchange registration process

Why it matters: 34% of their sales come from China, but moving profits out of the country just got harder.

---

Risks to Keep You Up at Night

China’s regulatory headaches:

• SAFE Circular 16: Blocks creative uses of foreign currency (like loans to partners)
• Big Brother reporting: Must share detailed investment plans with Chinese authorities
• Red tape delays: A 1-month paperwork wait for basic operational tweaks

---

Outside Forces to Watch

China’s "negative list" tightens:

• New rules limit where foreign-funded companies (like Dogness) can invest domestically
• Every foreign investment now requires detailed disclosures to Chinese commerce departments

---

What We’re Missing

The annual report skips critical details investors care about:

• No clear numbers on revenue growth or profit margins vs. last year
• No update on U.S. retail partnerships or R&D progress
• No comparison to competitors’ performance

This lack of transparency makes it harder to assess true financial health.

---

TL;DR for Investors
Dogness faces a cash flow obstacle course in China:

• 4-week delays to make basic operational changes
• Renminbi can’t fund anything beyond dog products (no side ventures)
• Mandatory investment disclosures to Chinese regulators

Bright spots? Tax breaks help, but converting profits to dollars is now riskier. Their U.S. expansion and R&D could offset China risks… but the report doesn’t share concrete progress.

Investment verdict: Proceed with caution. While Dogness operates in a growing pet products market, China’s regulatory squeeze and the company’s limited transparency make this a higher-risk play. Watch for updates on their U.S. strategy and cash management.

Remember: This isn’t advice—just a friend’s take on their annual report! 🐶📉